Mean EDSS Score (for the pooled core study and the extension).
Reproduced with permission from Sage Publications Ltd. Confavreux C et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Multiple Sclerosis 2012.